Two lessons for UK investors from Warren Buffett’s annual letter

Warren Buffett’s annual letter contained a lot of investing insight. Here are two themes I found relevant to me as a UK investor.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Over the weekend, Berkshire Hathaway released Warren Buffett’s annual letter to shareholders. Each year, the legendary investor shares his wisdom for all to read. Here are two points from the latest letter which I found interesting as a UK investor.

Finding value in the current market

What struck me most about the letter is how quiet Buffett was about his activities over the past year. He spoke less about looking for major acquisitions than he has done in recent years. But he also didn’t talk much about opening new holdings in listed companies. Indeed, the share purchase he talked most about was one in his own company.

So, Buffett appears to feel that Berkshire Hathaway is undervalued by the stock market. But he doesn’t seem to feel that there is much value in the sorts of companies he likes in the wider market. However, I did notice some changes in Berkshire’s list of largest shareholdings. For example, it now contains pharma names such as Merck and AbbVie. That suggests that over the past year, Buffett has seen opportunity in the pharma sector. Drug patents and distribution networks form the sort of economic moat Buffett likes in a business.

Shares in British pharma GSK continue to trade close to their lowest price for years. GSK has signalled a coming dividend reduction, and the market is nervous about the company’s drugs pipeline. But Buffett’s growing position in pharma made me wonder if shares like GSK might currently offer significant value. Buffett didn’t mention GSK, but his renewed enthusiasm for pharma blue chips has put GSK on my watchlist again.

Warren Buffett’s annual letter on share buybacks

A lot of discussion in Warren Buffett’s annual letter concerned share buybacks. That is where a company buys its own shares and cancels them. By reducing the total number of shares in circulation that way, the company effectively increases the proportion of the company owned by each share. As Buffett said, “The process offers a simple way for investors to own an ever-expanding portion of exceptional businesses”.

The numbers can look small by share, but the bigger picture shows the potential significance. For example, due to an Apple buyback, Berkshire’s stake in Apple actually grew in recent years even though it sold millions of Apple shares.

Buybacks elicit mixed reactions. Buffett’s annual letter set out how they effectively increase one’s stake in a company. But some investors would prefer a company to put the money to use to grow a business or pay a dividend, rather than buying their own shares. This is a question I am considering when looking at bank shares. Last year when dividend payments were restricted by the UK’s banking regulator, so were buybacks. But buybacks are now allowed again.

My holding in Standard Chartered is under water. In its recent results, the emerging markets bank announced a $254m buyback. Does that signal that it doesn’t see better opportunities to deploy that cash in its growth markets? Buffett sees some buybacks as creating value. But they also provide an investor with a moment to consider why a company thinks a buyback is the best use of the money involved. For Standard Chartered, I regard it as negative that they can’t deploy the $254m more profitably in growing the business.

christopherruane owns shares of Standard Chartered. The Motley Fool UK owns shares of and has recommended Apple and Berkshire Hathaway (B shares). The Motley Fool UK has recommended GlaxoSmithKline and Standard Chartered and recommends the following options: short January 2023 $200 puts on Berkshire Hathaway (B shares), short March 2021 $225 calls on Berkshire Hathaway (B shares), and long January 2023 $200 calls on Berkshire Hathaway (B shares). Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Santa Clara offices of NVIDIA
Investing Articles

Nvidia stock price forecast: could we see $300 in 2026?

Nvidia stock has paused for breath recently. However, Wall Street analysts seem to believe that it’s just a matter of…

Read more »

Older Man Reading From Tablet
Investing Articles

How to shelter a SIPP from a nasty stock market crash

Edward Sheldon outlines some simple strategies that could help SIPP investors protect their wealth against an equity market meltdown.

Read more »

ISA coins
Dividend Shares

4 UK shares that could provide a 10%+ annual ISA return

Jon Smith points out several stocks that could be included in a diversified ISA portfolio to help generate a yield…

Read more »

British pound data
Investing Articles

3 shares to consider buying as the FTSE 100 plummets

For those with cash on the sidelines and a long-term horizon, an equity market slump is less of a crisis…

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

2 FTSE 100 blue-chips to consider for a Stocks and Shares ISA before 5 April

Looking for ideas for a Stocks and Shares ISA before the forthcoming allowance deadline? Ben McPoland highlights two FTSE 100…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

How much will you need in a SIPP to earn a £3k monthly passive income in 2053?

A SIPP can be an exceptional wealth-building tool. Royston Wild explains how -- and reveals a top FTSE 100 dividend…

Read more »

Happy retired couple on a yacht
Investing Articles

3 easy steps to target a £1,000,000 Stocks and Shares ISA!

Looking to get a seat on millionaire's row? Royston Wild reveals three top strategies that could supercharge your Stocks and…

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

3 things to do right now as the annual ISA deadline looms!

With the ISA contribution deadline less than three weeks away, our writer runs through a trio of things he has…

Read more »